A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Inclusion Criteria:

Pathologically confirmed Stage IIIB NSCLC with malignant pleural effusion, or Stage IV disease
Measurable disease on CT scan (by the Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 (which means able to independently care for self and to perform light work) .
Adequate blood counts
Adequate liver and kidney function
Subjects or their legal representatives must be able to read, understand and provide written informed consent to participate in the trial.

Exclusion Criteria:

Predominant Squamous Cell NSCLC histology.
History of treatment for NSCLC with chemotherapy, biological therapy, immunotherapy (surgery or radiation therapy are accepted)
Brain (CNS) metastasis by head CT scan or MRI
Subjects with history of prior malignancy except for curatively treated basal cell carcinoma of the skin; cervical intra-epithelial neoplasia; or localized prostate cancer with a current prostate specific antigen (PSA) of < 4.0 mg/dL. Subjects with other curatively treated malignancies who have no evidence of metastatic disease and >2 year disease free interval may be entered after discussion with the Medical Monitor.
History of bleeding disorders, particularly coughing up ≥ ½ teaspoon bright red blood during the last 3 months
Certain cardiac disorders such as recent myocardial infarction (MI), severe congestive heart failure, certain types of abnormal cardiac rhythm
Uncontrolled high blood pressure despite medications
Uncontrolled, clinically significant active infection.
Known HIV
Known hypersensitivity to any of the components of CA4P, paclitaxel, carboplatin, bevacizumab, or radiologic contrast dyes.

Details of the above and additional inclusion and exclusion criteria can be discussed with an investigator.